Associations between the initial concentration of serum TNF alpha and effects due to increasing a dose of Infliximab, and between effects of infliximab and the concentration of serum IL-6

Associations between the initial concentration of serum TNF alpha and effects due to increasing a dose of Infliximab, and between effects of infliximab and the concentration of serum IL-6 - Associations between the initial concentration of serum TNF alpha and effects due to increasing a dose of Infliximab, and between effects of infliximab and the concentration of serum IL-6

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009887

Enrollment

100

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

When 3mg/kg of infliximab brings poor results to RA patients, we will change a dose of infliximab according to the initial concentration of serum TNF alpha. If the initial concentration of serum TNF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with more than 20 years at the time of informed consent 2. Patients with oral methotrexate 3. Patients with informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with severe infectious disease 2. Patients with active tuberculosis 3. Patients with allergy to infliximab or mouse protein 4. Patients with demyelinated disease 5. Patients with congestive heart failure

Design outcomes

Primary

Measure	Time frame
Disease Activity Score-28 (DAS28-CRP/ESR) Simplified Disease Activity Index (SDAI) Clinical Disease Activity Index (CDAI)	—

Secondary

Measure	Time frame
Van der Heijde' modified Sharp score	—

Countries

Japan

Contacts

Public ContactHiroshi Okuno

Tohoku University Hospital Orthopaedic surgery

okuno@med.tohoku.ac.jp022-717-7245

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026